Compound 8a(Dong-A University)(Compound 8a(Dong-A University)) - 药物靶点：RdRp_在研适应症：登革热，流感病毒感染，SARS-CoV-2 急性呼吸道疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

RdRp

作用方式

抑制剂

作用机制

RdRp抑制剂(RNA-引导的RNA聚合酶抑制剂)

治疗领域

感染呼吸系统疾病

在研适应症

登革热流感病毒感染SARS-CoV-2 急性呼吸道疾病

非在研适应症-

原研机构

Dong-A University

在研机构

Dong-A University

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Compound 8a(Dong-A University) 相关的临床结果

登录后查看更多信息

100 项与 Compound 8a(Dong-A University) 相关的转化医学

登录后查看更多信息

100 项与 Compound 8a(Dong-A University) 相关的专利（医药）

登录后查看更多信息

1

项与 Compound 8a(Dong-A University) 相关的文献（医药）

2023-03-01·Bioorganic & Medicinal Chemistry Letters

Synthesis and biological evaluation of new β-D-N4-hydroxycytidine analogs against SARS-CoV-2, influenza viruses and DENV-2

Article

作者: Nam, Ye Eun ; Ahn, Soo Bin ; Choi, Se Myeong ; Jang, Yejin ; An, Yeon Jin ; Kim, Meehyein ; Choi, Eun Rang ; Cho, Jong Hyun ; Seo, Eun Woo

Drug repurposing approach was applied to find a potent antiviral agent against RNA viruses such as SARS-CoV-2, influenza viruses and dengue virus with a concise strategy of small change in parent molecular structure. For this purpose, β-D-N⁴-hydroxycytidine (NHC, 1) with a broad spectrum of antiviral activity was chosen as the parent molecule. Among the prepared NHC analogs (8a-g, and 9) from uridine, β-D-N⁴-O-isobutyrylcytidine (8a) showed potent activity against SARS-CoV-2 (EC₅₀ 3.50 μM), Flu A (H1N1) (EC₅₀ 5.80 μM), Flu A (H3N2) (EC₅₀ 7.30 μM), Flu B (EC₅₀ 3.40 μM) and DENV-2 (EC₅₀ 3.95 μM) in vitro. Furthermore, its potency against SARS-CoV-2 was >5-fold, 3.4-fold, and 3-fold compared to that of NHC (1), MK-4482 (2), and remdesivir (RDV) in vitro, respectively. Ultimately, compound 8a was expected to be a potent inhibitor toward RNA viruses as a viral mutagenic agent like MK-4482.

100 项与 Compound 8a(Dong-A University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
登革热	临床前	韩国	Dong-A University	2023-02-08
流感病毒感染	临床前	韩国	Dong-A University	2023-02-08
SARS-CoV-2 急性呼吸道疾病	临床前	韩国	Dong-A University	2023-02-08